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Abstract 
Griseofulvin (1) is an important antifungal agent that has recently received attention due to its 
antiproliferative activity in mammalian cancer cells. Comprehensive SAR studies have led to the 
identification of 2’-benzyloxy griseofulvin 2, a more potent analogue with low micromolar 
anticancer potency in vitro. Analogue 2 was also shown to retard tumor growth through inhibition 
of centrosomal clustering in murine xenograft models of colon cancer and multiple myeloma. 
However, similar to griseofulvin, compound 2 exhibited poor metabolic stability and aqueous 
solubility. In order to improve the poor pharmacokinetic properties, 11 griseofulvin analogues were 
synthesized and evaluated for biological activity and physiological stabilities including SGF, 
plasma, and metabolic stability. Finally, the most promising compounds were investigated in 
respect to thermodynamic solubility and formulation studies. The 2’-benzylamine analogue 10 
proved to be the most promising compound with low µM in vitro anticancer potency, a 200-fold 
increase in PBS solubility over compound 2, and with improved metabolic stability. Furthermore, 
this analogue proved compatible with formulations suitable for both oral and intravenous 
administration. Finally, 2’-benzylamine analogue 10 was confirmed to induce G2/M cell cycle 
arrest in vitro. 
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Chemical compounds studied in this article 
Griseofulvin (PubChem CID: 441140) 
1 Introduction 
 
Griseofulvin (1), a natural product from Penicillium griseofulvum, was first discovered in 1939 and 
has since 1958 been known for its antifungal properties in guinea pigs and man (Figure 1) [1–3]. 
Since then, more than 400 analogues have been synthesized and in more recent years the compound 
class has received renewed interest due to findings of anticancer effects [4–7]. Griseofulvin has 
been identified as a tubulin binder that disrupts tubulin polymerization and microtubule dynamics 
[8,9] and was in 2007 shown to inhibit centrosomal clustering in vitro [10]. While normal cells have 
exactly two centrosomes at the onset of mitosis, tumor cells often have supernumerary centrosomes 
that lead to formation of multiple spindle poles. To avoid lethal asymmetric cell divisions, cancer 
cells rely on a dynamic process called centrosomal clustering to form pseudo-bipolar spindles and 
thus ensure appropriate cell division. Consequently, inhibition of centrosomal clustering may 
constitute a novel therapeutic strategy in oncology, by selective eradication of cancer cells with 
supernumerary centrosomes [11–13].  
Following this discovery, we have published three SAR studies covering more than 60 griseofulvin 
analogues with structural modifications to the 4, 5, 6, 2’, 3’, and 4’ positions [14–16] that were 
tested against multiple cancer cell lines. The endeavor led to identification of a new griseofulvin 
analogue, the 2’-benzyloxy analogue 2, that exhibited a 25-fold activity increase as a centrosome 
clustering inhibitor compared to 1 (Figure 1). In vivo studies confirmed analogue 2 to retard tumor 
growth through  inhibition of centrosomal clustering in murine xenograft models of colon cancer 
and multiple myeloma [14,17]. 
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Figure 1. Chemical structure of griseofulvin (1) with IUPAC recommended numbering and ring 
designation and the 2’-benzyloxy griseofulvin analogue 2. 
    
While griseofulvin analogues show potential as small molecule therapeutics in cancer treatment, the 
compounds generally suffer from poor pharmacokinetic properties including low solubility and 
metabolic instability [16,18]. In order to further our studies of griseofulvin derivatives, we herein 
report the synthesis and biological evaluation of 11 griseofulvin analogues (6 reported for the first 
time) with different 2’-substitution patterns. In addition to biological activity, griseofulvin (1) and 
analogues hereof were also subjected to pharmacokinetic studies involving stability in simulated 
gastric fluid (SGF) and plasma, plasma protein binding (PPB) as well as metabolic stability. Finally, 
thermodynamic solubility in phosphate buffered saline (PBS) and formulation studies were 
performed on the most promising analogues. 
 
2 Results and Discussion 
 
2.1 Synthesis 
 
The strategy used for preparation of the griseofulvin analogues was first described by Stephenson 
and co-workers [19] and later modified by Rønnest and colleagues (Scheme 1) [14,15]. 
Griseofulvin (1) was hydrolyzed to griseofulvic acid (3) and then converted into the 2’-chloro 
derivative 4 with phosphoryl chloride and lithium chloride in 1,4-dioxane. 2’-Chloro griseofulvin 4 
was treated with a suitable amine or alcohol nucleophile (RH) in the presence of 1,8-
diazabicycloundec-7-ene (DBU) to yield the desired product with the general structure 5. 
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Scheme 1. Overview of the synthetic strategy used for preparation of the 2’-modified griseofulvin 
analogues with the general structure 5. 
 
2.2 Compounds 
 
In our previously reported SAR studies, multiple 2’-oxy modified griseofulvin analogues were 
synthesized and evaluated. Here, a series of para-substituted 2’-benzyloxy analogues as well as the 
4’-oxime of 2 were found to have activity similar to compound 2 [14,15]. For this reason, the 2’-(4-
methylbenzyloxy) analogue 6, the 2’-(4-fluorobenzyloxy) analogue 7, the 2’-(4-
trifluoromethylbenzyloxy) analogue 8, and the 4’-oxime analogue 9 were included in the current 
study (Figure 2).  
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Figure 2. Previously reported 2’-oxy modified griseofulvin analogues with antiproliferative activity 
comparable to compound 2.  
 
In addition to these previously synthesized inhibitors, six new analogues were prepared. To 
examine the importance of the 2’-heteroatom and potentially enhance solubility, a similar series of 
2’-amino modified analogues, 10-12, was synthesized. Furthermore, as all previously reported 2’-
benzyloxy analogues have contained an unbranched linker, the 2’-tertiary amino analogue 13 as 
well as the two 2’-phenethyl modified analogues, 14 and 15, were also prepared (Figure 3).  
In total, 12 compounds consisting of griseofulvin (1), five previously reported 2’-oxy modified 
analogues (6-9), and six new analogues (10-15), were investigated. 
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Figure 3. The four 2’-amino analogues 10-13 and two 2’-phenethyl modified compounds 14 and 
15. 
 
2.3 Biological evaluation 
 
The activity of 1 was measured as 25.0 ± 4.9 µM and 22.4 ± 5.4 µM against the human epithelial 
cancer cell line MDA-MB-231 and the human osteosarcoma cancer cell line U2OS, respectively. 
As evident from Table 1, all tested analogues exhibited improved biological activity compared to 1 
against both cancer cell lines. The previously reported analogues 2, 6, and 9 and the two new 2’-
amino modified analogues 10 and 13 were the most potent and showed an approximate 10-fold 
increase in activity over 1. Except for 6, para-substitution on the 2’-aryl moiety led to a decrease in 
activity. Both 2’-oxy linker modified analogues 14 and 15 displayed a decrease in activity 
compared to 2. As the additional methyl group in these compounds would likely decrease aqueous 
solubility, 14 and 15 were not included in the following pharmacokinetic studies. 
 
Table 1. Anticancer activity of griseofulvin and analogues against two human cancer cell lines. 
Compound MDA-MB-231 
IC50 (µM) 
U2OS 
IC50 (µM) 
1 25.0 ± 4.9 22.4 ± 5.4 
2 1.7 ± 0.2 1.3 ± 0.3  
6 1.7 ± 0.2 1.3 ± 0.3 
7 3.3 ± 1.6  2.6 ± 0.2 
8 6.6 ± 1.5 5.6 ± 1.1 
9 1.4 ± 0.4 1.2 ± 0.1 
10 3.2 ± 1.0 2.1 ± 0.1 
11 8.2 ± 1.8  6.9 ± 0.4 
12 5.2 ± 2.4 2.6 ± 0.3 
13 3.5 ± 1.6 1.9 ± 0.4 
14 7.1 ± 1.1 1.6 ± 0.2 
15 17.1 ± 5.0 13.7 ± 2.2 
 
2.4 Plasma stability 
 
Variations within ± 20% is considered within the uncertainty of this assay and the numbers indicate 
high stability. Thus, 1 and all tested analogues exhibited excellent stability in both rat and mouse 
plasma (Table 2) with values ranging from 87 to 117%.  
 
2.5 Simulated gastric fluid stability 
 
To identify acid sensitive compounds that would be incompatible with oral administration, the 
analogues were subjected to a SGF stability assay (Table 2). SGF was designed to mimic the fasted 
stomach and contained HCl, NaCl, and pepsin at pH 1.2. The 2’-oxy modified analogues, 2 and 6-9, 
generally showed SGF stability similar to 1. The 2’-amino modified analogues 10-12 exhibited 
slightly lower stability compared to the 2’-oxy analogues. Interestingly, 13 proved highly unstable 
in SGF with only 15% of the parent compound remaining after 2 h.   
 
2.6 Metabolic stability 
 
Metabolic stability was evaluated using liver microsomes from mice and rats and determined as 
intrinsic clearance (CLint). As evident from SGF stabilities, the 2’-benzylmethylamine 13 was 
significantly less stable against metabolic degradation compared to the other compounds tested. 
This is likely attributed to easier protonation and/or cleavage of the 2’-tertiary amino substituent 
compared to the secondary amine- and oxy-substituents. In contrast to the trend observed for SGF 
stability, exchange of the 2’-enol moiety for the corresponding enamine generally increased 
metabolic stability against both rat and mouse microsomes. Most interesting was the potent 2’-
amino analogue 10 that showed a 2- and 4-fold increase in metabolic stability against rat and mice 
liver microsomes, respectively. This is likely explained by the increased hydrophilicity of 10-12 
(vide infra). The results also revealed that the aromatic moiety introduced at the 2’-position was not 
a metabolic hotspot as both plasma and metabolic stabilities of the griseofulvin derivatives 
(compounds 2-12) were comparable to the parent drug 1.  
 
2.7 Plasma protein binding 
 
Griseofulvin (1) was shown to have medium PPB with a percentage of fraction unbound (%fu) 
calculated to 22% and 43% in rat and mouse, respectively. While all analogues showed higher PPB 
than 1, the 2’-oxy modified compounds generally showed the highest PPB.  
 
Table 2. Pharmacokinetic data on compounds 1-13. 
Cmp 
Biological stability (% compound 
remaining after 120 min) 
Metabolic stability 
CLint (mL/min/mg protein) 
PPB (%fu) 
 Rat plasma Mouse plasma SGF Rat Mouse Rat plasma Mouse plasma 
1 107 107 73 56.6 ± 2.1 135 ± 1 21.6 ± 1.6 42.7 ± 2.0 
2 101 91 62 45.0 ± 3.8 120 ± 9 2.7 ± 0.1 11.2 ± 2.8 
6 89 102 68 60.2 ± 3.2 67.0 ± 4.0 1.8 ± 0.7 1.8 ± 0.4 
7 109 102 62 44.9 ± 1.0 81.7 ± 3.1 2.2 ± 0.1 2.9 ± 0.5 
8 108 92 75 30.7 ± 2.1 17.4 ± 1.2 1.1 ± 0.1 2.5 ± 0.3 
9 102 87 81 59.1 ± 4.2 104 ± 2 1.4 ± 0.1 4.3 ± 2.8 
10 116 117 52 28.0 ± 1.72 33.7 ± 1.1 11.1 ± 0.3 14.1 ± 1.7 
11 111 107 54 25.2 ± 2.6 47.4 ± 1.6 5.5 ± 0.1 11.0 ± 0.2 
12 92 108 54 25.5 ± 2.4 40.8 ±  2.2 9.4 ± 0.2 13.2 ± 0.1 
13 106 104 15 268 ± 14 358 ± 41.6 6.0 ± 0.6 8.7 ± 0.7 
SGF = simulated gastric fluid; CLint = intrinsic clearance; PPB = plasma protein binding; fu = 
fraction unbound.  
 
2.8 Thermodynamic solubility 
 
On the basis of activity and biologic stability results, thermodynamic solubility in PBS buffer was 
determined for the most promising analogues, 2, 9, and 10. While the 2’-oxy compounds 6 and 7 
showed similar activity and pharmacokinetic properties, the hydrophobicity constants of the methyl 
and trifluoromethyl group are both positive compared to hydrogen and were expected to result in 
poorer aqueous solubility than 2. The approved drug griseofulvin (1) is known to have poor aqueous 
solubility [18] and improving solubility is therefore of high importance. The solubility of 1 (7.7 
µg/mL) measured in PBS buffer at 22 °C is in agreement with earlier reported values measured in 
water at temperatures between 15 °C and 30 °C [20]. With 1 as reference, 2 and 9 had PBS 
solubility approximately 25- and 2.5-fold lower, respectively, whereas 10 exhibited roughly a 10-
fold improvement in solubility over 1 (Table 3). As expected, introduction of the secondary amine 
in 10 increased PBS solubility significantly. Table 3 also shows that there is no correlation between 
the thermodynamic solubility and clogP. As 9 is an isomeric mixture of E and Z oxime isomers, the 
thermodynamic solubility was calculated from the total chromatogram peak areas of the two 
isomers. The ratios between the minor and major isomers were 1:1.8 in acetonitrile and 1:1.6 in 
PBS buffer, as measured by HPLC, and 1:1.5 in CDCl3, as measured by 1H NMR. 
 
Table 3. Thermodynamic solubility and clogP of 1 and the most promising analogues, compounds 
2, 9, and 10.  
Compound 
Thermodynamic solubility 
(µg/mL) 
clogPa 
1 7.7 2.17 
2 0.3 3.90 
9 3.0 3.91 
10 62 3.58 
a cLogP partition coefficient was calculated according to Viswanadhan et al. [21] using Chemicalize 
software by ChemAxon. 
 
 
2.9 Formulation experiments for dosage delivery in clinical trials 
 
For investigation of dosage delivery for in vivo experiments, a series of formulation experiments 
were also performed on the three analogues 2, 9, and 10. For oral/gastrointestinal delivery (“oral 
formulation”), viscous liquid polyethylene glycol (PEG) 400 and solid matrix PEG8000 dosage 
forms were studied. PEG400 and PEG8000 can be further processed into final pharmaceutical 
products such as tablets/capsules and were designed with an active pharmaceutical ingredient (API) 
concentration of 5 mg/mL. For intravenous infusion (“IV solution”), a “water for injection” (WFI) 
dosage solution consisting of polysorbate 80 and poloxamer 188 (both at 5 mg/mL) was chosen. 
The WFI solution contained API at 1 mg/mL. The stability of the griseofulvin analogues in the 
different dosage forms at both 5 and 25 °C were measured by HPLC over a period of 30 days 
(Table 4).  
Although 10% PEG400 was needed for dissolution of 2 in PEG8000, all three analogues were 
easily dissolved and remained stable in low and high molecular weight PEG at both 5 and 25 °C. 
Analogues 2 and 10 were easily solubilized in water (WFI) when applying a mixture of polysorbate 
80 and poloxamer 188 surfactants. At 5 °C, both analogues showed no signs of degradation, 
however, at 25 °C only 9 remained stable. Due to the low aqueous solubility of 2, work on this 
compound was challenging and resulted in an unstable dosage form. The use of corn oil as an oral 
absorption enhancer was also investigated. However, these experiments proved unsuccessful as 
sedimentation formed in all three solutions upon cooling after dissolution at elevated temperatures. 
 
Table 4. Stability study of analogues 2, 9, and 10 in three different types of dosage forms. Positive 
(+) stabilities were assigned when the compounds did not show signs of degradation in their 
respective chromatograms after 30 days at the described conditions. The concentration of API was 5 
mg/mL for PEG400 and PEG8000 and 1 mg/mL liquid WFI, unless otherwise stated.  
Cmp 
Liquid PEG400 stability 
(5/25 °C) 
Solid PEG8000 stability  
(5/25 °C) 
Liquid WFI stability 
(5/25 °C) 
2 +a/+a +b/+b,c -/- 
9 +/+ +/+ +/+ 
10 +/+ +/+ +/- 
aAPI 10 mg/mL; bcontains 10% PEG 400; c4% degradation detected after 33 days; PEG: 
polyethylene glycol; WFI = water for injection. 
 
2.10 Cell cycle analysis 
 
With 10 exhibiting the most promising combination of potency and physico-chemical properties, 
this analogue was subjected to a cell cycle analysis to investigate if its mechanism of action was 
similar to griseofulvin. Both 1 and 2 have previously been confirmed to exhibit antiproliferative 
effect on human cancer cells and to cause G2/M arrest [10,17]. Cell cycle analysis of U2OS cells 
treated with 1 or 10 was performed by flow cytometry using propidium iodide staining. As evident 
from Figure 4, 1 and 10 both induced G2/M arrest in a concentration dependent manner. In 
agreement with the anticancer activity against U2OS (Table 1), analogue 10 exhibited more than a 
10-fold increase in potency over 1. Based on these findings and as expected, we conclude that 
analogue 10 works by a similar mechanism of action as 1 and 2. Indeed, this is of little surprise 
since 2 and 10 are structurally highly similar (only the 2’-oxygen has been exchanged for an NH). 
 Figure 4: Cell cycle analysis of exponentially growing U2OS cells treated with griseofulvin (1), 
analogue 10, or vehicle (DMSO) for 24 hours. A) Cell cycle distribution showing the percentages of 
cells in G0/G1, S, and G2/M phases. Bars indicate averages ± SD from two independent 
experiments. B) Examples of representative cell cycle histograms based on gated propidium iodide 
staining. Bars indicate cell populations in the G0/G1 (M1) and G2/M (M2) phases, respectively.  
 
 
3 Conclusion 
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Based on our earlier studies on the anticancer properties of griseofulvin (1) and analogues, six new 
analogues were synthesized and evaluated along with four of our previously reported 2’-oxy 
modified analogues [14,15]. The most potent compounds against the cancer cell lines MDA-MB-
231 and U2OS were 2, 6, 7, 9, 10, and 13 with IC50-values ranging from 1-3 µM, an approximate 
10-fold increase in activity over 1. Increasing the bulkiness of the 2’-oxy linker of 2 resulted in 
decreased activity against the cancer cell lines as evident from the 2’-phenethyl compounds 14 and 
15. With the exception of the 2’-tertiary amine 13, pharmacokinetic evaluation of the analogues 
indicated acceptable biological and metabolic stabilities of all compounds. The three most 
promising analogues, 2, 9, and 10, were further subjected to thermodynamic solubility- and 
formulation studies. Thermodynamic solubilities in PBS were determined to 0.3, 3, and 62 µg/mL 
for compounds 2, 9, and 10, respectively. When comparing these values to griseofulvin (1), an 
approved drug with a low PBS solubility of 7.7 µg/mL, 10 stood out as a promising analogue. 
Furthermore, the three compounds were investigated in formulation experiments for 
oral/gastrointestinal delivery and intravenous infusion. While all analogues were soluble and stable 
in the oral PEG400 or PEG8000 formulations, only 9 and 10 was compatible with a WFI solution 
for intravenous infusion.  
Based on the biological and physico-chemical data obtained, the new 2’-benzylamine analogue 10 
has proven the most promising lead for future SAR studies. Compared to 1, analogue 10 exhibited a 
20-fold increase in biological activity with IC50 = 3.2 ± 1.0 µM and 2.1 ± 0.1 µM against the MDA-
MB-231 and U2OS cancer cell lines, respectively. Furthermore, 10 exhibited good SGF, plasma, 
and metabolic stabilities with the latter being several folds better than for 1. Finally, analogue 10 
was confirmed to exert its anticancer effects through induction of G2/M cell cycle arrest in vitro as 
has previously been documented for both 1 and 2.    
For future studies, it should be worth considering the incorporation of an oxime moiety into 
analogue 10 for an additional boost to aqueous solubility. As oxime 9 exhibited a 10-fold increase 
in PBS solubility compared to compound 2 without loss of potency, this presents an attractive 
modification to pursue.  
 
4 Materials and methods 
 
4.1 Chemistry 
 
Starting materials, reagents, and solvents were purchased from Sigma-Aldrich and used without 
further purification, unless otherwise noted. All solvents were of analytical grade and dried when 
necessary over 4 Å activated molecular sieves and water content was determined to be less than 20 
ppm by Karl Fischer titration on a Metrohm 899 – Coulometer. For reactions carried out under 
argon the glassware was dried before use, employing the following procedure: heating was applied 
with a heat gun while the glassware was evacuated (16 Torr), the evacuation was followed by argon 
flushing. Evacuation and flushing were applied several times under continuous heating, and finally 
the glassware was allowed to cool to room temperature under argon before use. Thin Layer 
Chromatography (TLC) was carried out on commercially available pre-coated plates (Merck 60, 
F254). Dry Column Vacuum Chromatography (DCVC) was performed according to a published 
procedure[22]. When concentrating on celite in vacuo for DCVC purification, high vacuum was 
also used.  
1H, 13C, HSQC, HMBC NMR spectra were recorded on a Bruker Ascend 400 Fourier transform 
spectrometer using an internal deuterium lock. 19F NMR Spectra were recorded on a Varian 
Mercury 300 B Fourier transform spectrometer. Solvents were used as internal standards when 
assigning 1H and 13C NMR spectra (δH: CHCl3 7.26 ppm, DMSO-d5 2.50; δC: CDCl3 77.16 ppm, 
DMSO-d6 39.52 ppm). HRMS was performed on a Bruker Daltronics maXis 3G QTOF-MS fitted 
with a Dionex Ultimate 3000 UHPLC. A Stuart Advanced Digital Melting Point SMP30 was used 
to determine melting point and they are reported uncorrected. Optical rotation was measured on a 
Perkin-Elmer 241 Polarimeter, and the values are given in degrees and concentrations are given in 
g/100 mL. 
 
4.2 Synthesis 
 
Compounds 2, 6, 7, 8, and 9 were prepared according to literature procedures.[14,15]  
 
4.2.1 (2S,6'R)-2'-(Benzylamino)-7-chloro-4,6-dimethoxy-6'-methyl-3H-spiro[benzofuran-2,1'-
cyclohexan]-2'-ene-3,4'-dione (10) 
 
To a stirred solution of 4 (1.07 g, 3 mmol) under argon in 1,4-dioxane (15 ml) was added 
benzylamine (0.66 ml, 6 mmol) followed by DBU (1.16 ml, 7.5 mmol). The solution was heated at 
50 oC for 21 h, and 95 oC for additional 45 min. The mixture was allowed to reach 22 oC, 
concentrated on celite and purified by DCVC: (⌀ = 40 mm) gradient eluted with 99:1 toluene:Et3N 
→ 81:18:1 toluene:MeCN:Et3N 2 % increment/50 mL fraction). The resulting light yellow solid 
was recrystallized from THF/heptane yielding 10 0.91 g (71 %) as light yellow crystals. Rf = 0.13 
(85:10:5 toluene:MeCN:Et3N); mp: 130-132 °C; [α]𝐷𝐷20 = +392° (c = 1.0 in CHCl3);  1H NMR (400 
MHz, CDCl3): δ 7.36-7.22 (m, 3H), 7.16 (d, J = 6.9 Hz, 2H), 6.16 (s, 1H), 5.28 (s, 1H), 4.91 (t, J = 
5.2 Hz, 1H), 4.16 (ABX, J = 24.0, 16.0 Hz, Δ = 17.9 Hz, 2H), 4.01 (s, 3H), 3.97 (s, 3H), 2.97– 2.82 
(m, 2H), 2.41-2.28 (m, 1H), 0.93-0.86 (d, J = 6.0 Hz, 3H); 13C NMR (101 MHz, CDCl3): δ 195.2, 
191.4, 168.3, 164.7, 158.0, 157.4, 136.2, 129.0 (2C), 128.0, 127.4 (2C), 104.7, 99.8, 97.4, 91.7, 
90.4, 57.2, 56.6, 47.3, 39.1, 37.4, 14.7;  HRMS (ESI+) 428.1279 calcd. for [M+H]+ 428.1259. 
 
4.2.2 (2S,6'R)-7-Chloro-4,6-dimethoxy-6'-methyl-2'-((4-methylbenzyl)amino)-3H-
spiro[benzofuran-2,1'-cyclohexan]-2'-ene-3,4'-dione (11) 
 
4-Methylbenzylamine (0.13 mL, 1 mmol) and DBU (0.19 mL, 1.25 mmol) was added to a stirred 
solution of 4 (0.18 g, 0.5 mmol) in dry 1,4-dioxane (2.5 mL). After heating to 80 °C for 15 h, the 
mixture was allowed to reach 22 °C and evaporated in vacuo resulting in a light brow gum. The 
residue was purified by flash column chromatography using eluent gradient MeCN/CH2Cl2 (3:7; 
v/v,) yielding 84.7 mg (38 %) 11 as a light yellow solid. Rf = 0.34 (MeCN/CH2Cl2 (3:7; v/v); [α]𝐷𝐷20 
= +410° (c = 0.50 in CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.11 (d, J = 8.0 Hz, 2H), 7.06 (d, J = 
8.1 Hz, 2H), 6.15 (s, 1H), 5.29 (s, 1H), 4.84 (t, J = 5.1 Hz, 1H), 4.11 (ABX, J = 14.6, 5.2 Hz, Δ = 
21.3 Hz, 2H), 4.01 (s, 3H), 3.97 (s, 3H), 2.96-2.84 (m, 2H), 2.38-2.32 (m, 1H), 0.89 (d, J = 6.3 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ 195.5, 191.4, 168.2, 164.7, 158.0, 157.4, 137.8, 133.1, 129.7, 
127.5, 104.7, 99.7, 97.4, 91.7, 90.4, 57.2, 56.6, 47.2, 39.1, 37.4, 21.2, 14.7; HRMS (ESI+) 442.1422 
calcd. for [M+H]+ 442.1416. 
 
4.2.3 (2S,6'R)-7-Chloro-2'-((4-fluorobenzyl)amino)-4,6-dimethoxy-6'-methyl-3H-
spiro[benzofuran-2,1'-cyclohexan]-2'-ene-3,4'-dione (12) 
 
To a stirred solution of 4 (0.36 g, 1 mmol) under argon in 1,4-dioxane (5 mL) was added 4-
fluorobenzylamine (0.23 mL, 2 mmol) followed by DBU (0.37 mL, 2.5 mmol). The solution was 
stirred for 6 h at 95 °C before cooling it to 22 °C and concentrating it on celite in vacuo. 
Purification by DCVC (⌀ = 20 mm) gradient eluted 100 toluene → 62.5:37.5 toluene:MeCN 2.5% 
increment/20 mL fraction (all solvents containing 1 % Et3N) yielded a white solid which was re-
crystallized from EtOAc/heptane resulting in 0.11 g (22 %) 12 as white crystals. Rf = 0.16 (70:28:2 
toluene:MeCN:Et3N); mp:  161-163 °C; [α]𝐷𝐷20 = +378° (c = 0.43, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 7.13 (dd, J = 8.5, 5.4 Hz, 2H), 6.98 (t, J = 8.6 Hz, 2H), 6.16 (s, 1H), 5.24 (s, 1H), 4.90 (s, 
1H), 4.20-4.06 (m, 2H), 4.02 (s, 3H), 3.98 (s, 3H), 2.96-2.79 (m, 2H), 2.44-2.24 (m, 1H), 0.89 (d, J 
= 6.2 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 195.6, 191.6, 168.4, 165.0, 162.6 (d, 1JCF = 246.4 
Hz), 158.2, 157.5, 132.1 (d, 4JCF = 3.2 Hz), 129.2 (2C, d, 3JCF = 8.2 Hz), 116.2 (2C, d, 2JCF = 21.6 
Hz), 104.9, 100.2, 97.6, 91.9, 90.6, 57.4, 56.8, 46.8, 39.3, 37.6, 14.9; 19F NMR (282 MHz, CDCl3) δ 
-114.7; HRMS (ESI+) found 446.1167 calcd. for [M+H]+ 446.1165. 
 
4.2.4 (2S,6'R)-2'-(Benzyl(methyl)amino)-7-chloro-4,6-dimethoxy-6'-methyl-3H-spiro[benzofuran-
2,1'-cyclohexan]-2'-ene-3,4'-dione (13)  
 
To a stirred solution of 4 (0.18 g, 0.5mmol) and 1,8-bis(dimethylamino)naphthalene,N,N,N′,N′-
tetramethyl-1,8-naphthalenediamine (Proton-sponge) (0.27 g, 1.25 mmol) in 1,4-dioxane (3 mL) 
under argon was added N-methyl-1-phenylmethanamine (0.13 mL, 1 mmol). The mixture was 
heated to 60 °C for 20 h and then at 85 °C for 20 h. The reaction was allowed to reach 22 °C and 
the solvent was evaporated in vacuo. The resulting brown gum was purified by flash column 
chromatography using MeCN:CH2Cl2 2:8 yielding 13 50.8 mg (23 %) as a white solid. Rf = 0.36 
(MeCN:CH2Cl2 2:8); [α]𝐷𝐷20 = +100° (c = 0.5 in CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.32-7.20 
(m, 3H), 7.08 (d, J = 7.1 Hz, 2H), 6.10 (s, 1H), 5.41 (s, 1H), 4.16 (AB, J = 16.3 Hz, Δ = 43.2 Hz, 
2H), 3.99 (s, 3H), 3.97 (s, 3H), 3.04-2.93 (m, 1H), 2.84 (dd, J = 16.8, 13.0 Hz, 1H), 2.71 (s, 3H), 
2.33 (dd, J = 16.8, 4.3 Hz, 1H), 0.85 (d, J = 6.7 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 195.4, 
191.7, 168.0, 164.7, 160.7, 157.7, 135.8, 128.9, 127.6, 127.0, 105.7 (2C), 92.1, 90.1, 57.2, 57.1, 
56.6, 40.6, 39.6, 38.6, 15.2; HRMS (ESI+) 442.1418 calcd. for [M+H]+ 442.1416. 
 
4.2.5 (2S,6'R)-7-Chloro-4,6-dimethoxy-6'-methyl-2'-((S)-1-phenylethoxy)-3H-spiro[benzofuran-
2,1'-cyclohexan]-2'-ene-3,4'-dione (14) 
 
To a stirred solution of 4 (0.36 mg, 1 mmol) in 1,4-dioxane (5 ml) under argon was added (S)-
phenylethanol (0.24 ml, 2 mmol) followed by DBU (0.37 ml, 2.5 mmol). The solution was heated at 
80 oC for 6½ h followed by 65 oC for additional 18 h. More (S)-phenylethanol (0.24 ml, 2 mmol) 
was added and the mixture was heated to 85 oC for 5 h and 65 oC for additional 90 h. The mixture 
was allowed to reach 22 oC and was concentrated on celite. Purification by DCVC: (⌀ = 20 mm) 
gradient eluted 100 toluene → 72.5:27.5 toluene:MeCN 2.5 % increment/20 mL fraction yielded 
0.20 g (45 %) 14 off white solid. Rf = 0.21 (85:15 toluene:MeCN); [α]𝐷𝐷20 = +224° (c = 0.51 in 
CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.26-7.17 (m, 3H), 7.02 (m, J = 5.2, 3.2 Hz, 2H), 6.15 (s, 
1H), 5.37 (s, 1H), 5.10 (q, J = 6.4 Hz, 1H), 4.05 (s, 3H), 4.00 (s, 3H), 2.95 (dd, J = 16.3, 13.0 Hz, 
1H), 2.82 (ddd, J = 13.0, 6.6, 4.4 Hz, 1H), 2.39 (dd, J = 16.3, 4.4 Hz, 1H), 1.47 (d, J = 6.4 Hz, 3H), 
0.98 (d, J = 6.6 Hz, 3H); 13C NMR (101 MHz, CDCl3): δ 197.3, 192.3, 169.8, 168.6, 164.5, 157.9, 
140.6, 128.9 (2C), 128.1, 125.0 (2C), 107.2, 105.5, 97.3, 91.0, 89.6, 78.0, 57.1, 56.6, 40.3, 36.5, 
23.8, 14.5; HRMS (ESI+) 465.1072 calcd. for [M+Na]+ 465.1075. 
 
4.2.6 (2S,6'R)-7-Chloro-4,6-dimethoxy-6'-methyl-2'-((R)-1-phenylethoxy)-3H-spiro[benzofuran-
2,1'-cyclohexan]-2'-ene-3,4'-dione (15) 
 
To a stirred solution of 4 (0.36 mg, 1 mmol) in 1,4-dioxane (5 ml) under argon was added (R)-
phenylethanol (0.24 ml, 2 mmol) followed by DBU (0.37 ml, 2.5 mmol). The solution was heated at 
65 oC for 18 h followed by 80 oC for additional 4 days. The mixture was allowed to reach 22 oC and 
was concentrated on celite. Purification by DCVC: (⌀ = 20 mm) gradient eluted 100 toluene → 
75:25 toluene:MeCN 2.5 % increment/20 mL fraction yielded 0.13 g (29 %) 15 as a colorless 
viscous liquid. Rf = 0.35 (70:30 toluene:MeCN); [α]𝐷𝐷20 = +114° (c = 0.10 , CHCl3); 1H NMR (400 
MHz, CDCl3) δ 7.38-7.20 (m, 5H), 6.17 (s, 1H), 5.42 (s, 1H), 5.11 (q, J = 6.3 Hz, 1H), 4.05 (s, 3H), 
4.00 (s, 3H), 3.00 (dd, J = 16.7, 13.5 Hz, 1H), 2.84-2.69 (m, 1H), 2.34 (dd, J = 16.7, 4.7 Hz, 1H), 
1.37 (d, J = 6.4 Hz, 3H), 0.97 (d, J = 6.7 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 197.1, 192.8, 
169.8, 168.8, 164.6, 157.7, 140.8, 128.8, 128.0, 125.1, 106.9, 105.3, 97.2, 90.9, 89.5, 77.4, 57.1, 
56.4, 39.8, 36.1, 23.4, 14.3; HRMS (ESI+) 465.1072 calcd. for [M+Na]+ 465.1075. 
 
4.2.7 Chromatographic systems 
 
Purity and solubility experiments by HPLC was performed on the following systems: 1) Waters 
e2629 separation module fitted with a Waters 2998 PDA detector and a Waters Symmetry 3.5 µm 
C18 column (4.6 x 75 mm) using eluents: A = water and B = MeCN (both solvents containing 0.1 
% formic acid). 2) Agilent 1100 series setup with autosampler, PDA detector, and a Phenomenex 
Luna 3μ C18 2 100 Å column (150 × 4.6 mm) using eluents: A = 95:5:0.1 MilliQ: MeCN:TFA and 
B = 0.1 % TFA in MeCN. In both cases, chromatograms were analyzed at 254 nm wavelength. 
Separations were performed in a total run time of 26 min under gradient conditions with a flow rate 
of 1 mL/min and sample injections of either 30 µL or 50 µL. Samples were eluted using the 
following gradient: 100% A in 2 min followed by a linear gradient from 0% to 95% B in 18 min 
and held constant for 2 min. At 23 min, solvent B was decreased from 95% to 0% and held constant 
for 3 min.  
 
4.3 Biological evaluation 
 
4.3.1 Anticancer activity 
 
Anticancer potency was determined as anti-proliferative activity against the human epithelial breast 
cancer cell line MDA-MB-231 and the human osteosarcoma cell line U2OS. MDA-MB-231 cells 
were cultivated in RPMI 1640 (Life Technologies) supplemented with 10% FCS (Invitrogen). 
U2OS cells were cultivated in DMEM + GlutaMAX (Life technologies), supplemented with 10% 
FCS (Invitrogen). All cell lines were maintained at 37°C and 5% CO2. For IC50 determination, cells 
were seeded on white bottom 96-well plates (Perkin Elmer) at a density of 2 x 104 cells/well and 
rested for 24 h before exposure to increasing compound concentrations or vehicle (DMSO). After 
72 h incubation, relative amounts of viable cells were determined with CellTiter Glo® Luminiscent 
Viability Assay (Promega) according to the manufacturer’s instructions. Luminescence was 
measured on an Infinite® 200 (Tecan) microplate reader. Each sample was measured in triplicate. 
Mean IC50 values ± SD were calculated from fitted dose-response curves from at least 3 
independent experiments. 
 
4.3.2 Cell cycle analysis 
 
Exponentially growing U2OS cells were treated with the indicated concentrations of inhibitor or 
vehicle for a period of 24 h. Following incubation, cells were collected, washed with PBS (1×), and 
fixed with ice cold 70% methanol. Approx. 1 million cells from each sample were stained with 
propidium iodide solution (2.5% RNase A (Molecular Probes); 1% propidium iodide (Applichem) 
in PBS) for 30 min at 37 °C. Cell cycle analysis was then performed on a BD Accuri™ C6 flow 
cytometer. The experiment was performed twice on two different days.  
 
4.4 Pharmacokinetic assays 
Pharmacokinetic assays were all performed by Cyprotex UK and were analyzed by LC-MS/MS 
using an internal standard.  
 
4.4.1 Plasma stability 
 
Plasma stability was measured in both rat and mouse plasma and given as the percent of parent 
compound remaining after 2 h using 5 time points. The assay was run at 37 °C with a compound 
concentration of 1 µM and at a final DMSO concentration of 2.5%. If necessary, the pH of the 
plasma was adjusted to pH 7.4 with either hydrochloric acid or sodium hydroxide. Reactions were 
terminated following 0, 15, 30, 60, 120 min by methanol containing internal standard. The sampling 
plate was centrifuged (2500 rpm, 45 min, 4 °C) and the supernatants from each point were pooled in 
cassettes of up to 4 compounds. Samples were analyzed for parent compound by LC-MS/MS using 
Cyprotex generic analytical conditions. The percentage of parent compound remaining at each time 
point relative to the 0 min sample was then calculated from LC-MS/MS peak area rations 
(compound peak area/internal standard peak area). 
 
4.4.2 Simulated gastric fluid stability 
 
Incubations were performed at a test or control compound concentration of 1 µM in SGF (pH 1.2), 
at 37 °C. The final DMSO concentration in the incubations was 2.5%. Reactions were terminated 
following 0, 15, 30, 60, and 120 min by methanol containing internal standard. The sampling plate 
was centrifuged (2500 rpm, 45 min, 4 °C) and the supernatants from each point were pooled in 
cassettes of up to 4 compounds. Samples were analyzed for parent compound by LC-MS/MS using 
Cyprotex generic analytical conditions. The percentage of parent compound remaining at each time 
point relative to the 0 min sample was then calculated from LC-MS/MS peak area rations 
(compound peak area/internal standard peak area). 
 
4.4.3 Metabolic stability 
 
Pooled liver microsomes (male CD1 mice and male Sprague Dawley rats) were purchased from a 
commercial supplier. Microsomes (final protein concentration 0.5 mg/mL), 0.1 M phosphate buffer 
pH 7.4, and test compound (final substrate concentration 3 µM; final DMSO concentration 0.25%) 
were pre-incubated at 37 °C prior to addition of NADPH (final concentration 1 mM) to initiate the 
reaction. The final incubation volume was 50 µL. A control incubation was included for each 
compound tested, where 0.1 M phosphate buffer pH 7.4 were added instead of NADPH (minus 
NADPH). Two control compounds were included with each species. All incubations were 
performed singularly for each test compound, for 0, 5, 15, 30, and 45 min. The control (minus 
NADPH) was incubated for 45 min only. The reactions were stopped by transferring 25 µL of 
incubate to 50 µL methanol at the appropriate time points. The termination plates were centrifuged 
at 2500 rpm for 20 min at 4 °C to precipitate protein. Following protein precipitation, the sample 
supernatants were combined in cassettes of up to 4 compounds, internal standard was added and 
samples were analyzed using Cyprotex generic LC-MS/MS conditions. 
 4.4.4 Plasma protein binding 
 
Solutions of test compound (5 µM, 0.5% final DMSO concentration) were prepared in buffer (pH 
7.4) and 100% species-specific plasma. The experiment was performed using equilibrium dialysis 
with the two compartments separated by a semi-permeable membrane. The buffer solution was 
added to one side of the membrane and the plasma solution to the other side. After equilibrium, 
samples were taken from both sides of the membrane. Standards were prepared in plasma and 
buffer and were incubated at 37 °C. Test compounds incubations were performed in duplicate. A 
control compound was included in each experiment. 
The solutions for each batch of compounds were combined into two groups (protein-free and 
protein-containing), then cassette was analyzed by LC-MS/MS using two sets of calibration 
standards for protein-free (7 points) and protein-containing solutions (6 points). Cyprotex generic 
LC-MS/MS conditions were used. Samples were quantified using standard curves prepared in the 
equivalent matrix. % fraction unbound (%fu) was calculated based on duplicate experiments. 
 
4.5 Thermodynamic solubility  
 
Saturated PBS solutions of the compounds was prepared by sonication and shaking and the HPLC 
chromatogram peak areas were used to calculate the respective solubility from the reference graphs. 
An external standard of benzoic acid in PBS was used and yielded an inter series variance of 
maximum 1.4%. The deviation in the peak area of benzoic acid in each series from the benzoic acid 
mean value in all the series was used as a correction factor. 
Two Eppendorf tubes with 1 mg compound in each were prepared (tube A and B). 1 mL PBS buffer 
(10 mM phosphate buffer, 2.7 mM KCl, 137 mM NaCl, pH 7.4) was added to tube A and tube A 
was subjected to sonication for 10 min at room temperature (Bransonic 1210E) followed by shaking 
on a shaking platform for 12 h. Tube A was spun down (14000 rpm, 10 sec) and the supernatant 
transferred to a HPLC sample tube (if precipitate was still present in the supernatant, centrifugation 
was repeated until no precipitate was visible). A reference absorption (at 254 nm) graph was made 
from dilution series of the compounds in MeCN: After 12 h, the compound in test tube B was 
dissolved in 1 mL MeCN and diluted further in MeCN to 100, 75, 50, 25, and 10 µg/mL. The 
samples were then analyzed by HPLC starting with the analogue saturated aqueous PBS buffer and 
then followed by the prepared acetonitrile solutions in the reverse order (low to high 
concentrations). From the compound peak area(s) in the HPLC chromatograms of the acetonitrile 
solutions a line fit (Y = aX) could be obtained and the solubility of the analogue in PBS buffer was 
calculated from the line’s slope and the compound’s peak area in PBS buffer. 
 
4.6 Formulation experiments 
 
4.6.1 Manufacturing of test samples 
 
PEG400 and corn oil: the API candidate was dissolved in PEG400 or corn oil at 70-80 °C followed 
by intensive vortex mixing. The final clear solutions were stored in 1.5 ml HPLC vials. PEG8000: 
the API candidate was dissolved in melted PEG8000 at 90-100 °C using magnetic stirring. If this 
method failed, the API was dissolved in PEG400 and the solution was then mixed with melted 
PEG8000. The hot melted PEG solution was cast as tablets in a plastic mold. WFI injection 
solution: the API candidate was dissolved in the surfactants at 70-80 °C and hot water was added 
very slowly. The solution was then cooled down to ambient temperature and stored in 4 mL HPLC 
vials.  
 
4.6.2 Sample preparation for investigating the stability of the formulation experiments 
 
For WFI formulations, 20 µL of sample was diluted to 200 µL with Milli-Q water (volume dilution 
x 10). For liquid and solid PEG formulations, 200 µL liquid or 50 mg solid was added to 1 mL 
CH2Cl2 and 1 mL Milli-Q water. The aqueous phase was extracted with further CH2Cl2 (1 mL) and 
the combined organic phase washed with Milli-Q water (1 mL). The organic phase was evaporated 
in vacuo (including high vacuum oil pump) and the residue dissolved in 0.8 mL (for liquid samples, 
volume dilution x 4) or 1 mL (for solid samples, 20 x dilution) MeCN. The samples were analyzed 
by HPLC. The aqueous phases from this extraction were also subjected to HPLC analysis and only 
trace amounts of UV active compounds were found. 
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7 List of captions 
 
7.1 Figures 
 
Figure 1. Chemical structure of griseofulvin (1) with IUPAC recommended numbering and ring 
designation and the 2’-benzyloxy griseofulvin analogue 2. 
 
Figure 2. Previously reported 2’-oxy modified griseofulvin analogues with antiproliferative activity 
comparable to compound 2. 
 
Figure 3. The four 2’-amino analogues 10-13 and two 2’-phenethyl modified compounds 14 and 
15. 
 
Figure 5: Cell cycle analysis of exponentially growing U2OS cells treated with griseofulvin (1), 
analogue 10, or vehicle (DMSO) for 24 hours. A) Cell cycle distribution showing the percentages of 
cells in G0/G1, S, and G2/M phases. Bars indicate averages ± SD from two independent 
experiments. B) Examples of representative cell cycle histograms based on gated propidium iodide 
staining. Bars indicate cell populations in the G0/G1 (M1) and G2/M (M2) phases, respectively.  
 
7.2 Schemes 
 
Scheme 1. Overview of the synthetic strategy used for preparation of the 2’-modified griseofulvin 
analogues with the general structure 5. 
 
7.3 Tables 
 
Table 1. Anticancer activity of griseofulvin and analogues against two human cancer cell lines. 
 
Table 2. Pharmacokinetic data on compounds 1-13. 
 
Table 3. Thermodynamic solubility and clogP of 1 and the most promising analogues, compounds 
2, 9, and 10. 
 
Table 4. Stability study of analogues 2, 9, and 10 in three different types of dosage forms. Positive 
(+) stabilities were assigned when the compounds did not show signs of degradation in their 
respective chromatograms after 30 days at the described conditions. The concentration of API was 5 
mg/mL for PEG400 and PEG8000 and 1 mg/mL liquid WFI, unless otherwise stated. 
 
 
